Live Breaking News & Updates on Kilmer Lucas Inc

Stay updated with breaking news from Kilmer lucas inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Soricimed to Investigate the Potential Benefit of SOR-C13 in the Treatment of COVID-19


Share this article
Share this article
MONCTON, NB, Dec. 17, 2020 /CNW/ - Soricimed Biopharma Inc., ( Soricimed ), a privately-held, science-based, clinical stage company focused on the development and commercialization of first-in-class targeted cancer therapeutics, today announced that it will investigate the potential therapeutic role its cancer drug candidate, SOR-C13, can play in helping relieve or prevent severe immune response to the SARS CoV-2 virus.
Soricimed is currently developing SOR-C13, a TRPV6 calcium channel inhibitor, for the treatment of solid-tumour cancers. SOR-C13 is designed to decrease calcium concentrations inside cancer cells to inhibit calcium-dependent cancer cell proliferation and induce the death of tumour cells overexpressing TRPV6. ....

United States , New Brunswick , Stephen Kilmer , Jack Stewart , Robert Bruce , Soricimed Biopharma , Kilmer Lucas Inc , National Public Relations , Drug Administration , Md Anderson Cancer Center , Canada Health , Soricimed Biopharma Inc , Chief Scientific Officer , National Research Council , Canada Industrial Research Assistance Program , Health Canada , Cancer Center , Peptide Drug Conjugates , Vivo Detection , Rich Tumours , Anti Cancer Peptides Derived , Media Relations , Titi Ajibose , Investor Relations , ஒன்றுபட்டது மாநிலங்களில் , புதியது பிரன்சுவிக் ,